Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and ...

NORCROSS, Ga., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with MASH cirrhosis and portal ...
Louisville Public Media

Indiana measure extending syringe services programs headed to governor

The Indiana Senate has approved changes to a bill extending state approval for syringe services programs for five years.
The Indiana Lawyer

Fight over GLP-1 compounding plays out in statehouses, courthouses

Since 2023, Eli Lilly and Co. has filed lawsuits against dozens of compound pharmacies, weight-loss centers and health spas that produced and sold copies of Mounjaro and Zepbound.

This Looming Drug Development Gap Could Impact Patients' Health

In this week’s edition of InnovationRx, we look at cheaper biologic drugs, Novo Nordisk’s $2 billion next-gen obesity drug deal, new ways of fighting cancer, and more.